Eplerenone
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Eplerenone and local guidelines before prescribing.
Mechanism
Selective mineralocorticoid receptor antagonist.
Uses
Heart failure after MI, heart failure with reduced EF.
Dosing
- Eplerenone | Post-MI LV dysfunction: 25 mg daily, increasing to 50 mg daily.
Cardiology: Ischaemic Heart Disease (ACS) › 1.33 Drug Reference Table - Eplerenone | 25 mg daily initially; increase to 50 mg daily if tolerated.
Cardiology: Heart Failure › 2.33 💊 Common Drugs and Adult Doses - Eplerenone , e.g. 25–50 mg twice daily. Fewer sex-hormone side effects, but less potent.
Endocrinology: Adrenal Disease - Eplerenone Primary aldosteronism | 25–50 mg twice daily (off-label for this use). Fewer sex-hormone side effects.
Endocrinology: Adrenal Disease
Side effects
Hyperkalaemia, renal impairment, dizziness; fewer endocrine effects than spironolactone.
Interactions
CYP3A4 inhibitors (clarithromycin, ketoconazole) contraindicated; ACE inhibitors, ARBs, potassium raise potassium.
Contraindications and cautions
Potassium above 5.0 mmol/L, eGFR below 30, strong CYP3A4 inhibitors
Monitoring
Potassium, creatinine
Pregnancy and breastfeeding
Avoid unless essential
Renal and hepatic impairment
Avoid in severe renal impairment
Overdose and reversal
Supportive; treat hyperkalaemia
Special advice
Monitor potassium and creatinine early and regularly.
More from the textbook: uses, cautions and other points
- Side effects - hyperkalaemia (check U&E regularly; caution with ACE inhibitors, ARBs, potassium supplements, CKD), gynaecomastia and breast pain with spironolactone (less with eplerenone).
Cardiology: Anatomy Physiology and Pharmacology - Spironolactone / eplerenone | MRAs; HFrEF survival; hyperkalaemia; gynaecomastia (spironolactone).
Cardiology: Anatomy Physiology and Pharmacology - ⚠️ Prescribing Pearls: Aspirin plus one P2Y12 inhibitor after ACS. Prasugrel is contraindicated after stroke or TIA. Never give nitrates with PDE-5 inhibitors or in RV infarction. Monitor potassium and creatinine with ACE inhibitors and eplerenone. Do not start beta blockers in shock or heart block.
Cardiology: Ischaemic Heart Disease (ACS) › 1.33 Drug Reference Table - Drugs : Spironolactone. Eplerenone.
Cardiology: Heart Failure › 2.20 💊 Mineralocorticoid Receptor Antagonists - Adverse effects : Hyperkalaemia. Renal dysfunction. Gynaecomastia with spironolactone. Menstrual or sexual adverse effects with spironolactone. Eplerenone is more selective for the mineralocorticoid receptor and causes fewer endocrine adverse effects.
Cardiology: Heart Failure › 2.20 💊 Mineralocorticoid Receptor Antagonists - Drugs acting on the system - ACE inhibitors, ARBs, spironolactone, eplerenone (all can raise potassium); heparin suppresses aldosterone (hyperkalaemia); NSAIDs reduce renin.
Endocrine: Anatomy Physiology and Pharmacology
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (4 mentions)
- Cardiology: Ischaemic Heart Disease (ACS) (2 mentions)
- Cardiology: Heart Failure (3 mentions)
- Endocrine: Anatomy Physiology and Pharmacology (2 mentions)
- Endocrinology: Adrenal Disease (5 mentions)
- Renal: Anatomy, Physiology and Pharmacology (4 mentions)
- Clinical pharmacology and prescribing: Adverse drug reactions, interactions and drug allergy (1 mention)
- Integrated cardiology chapter (5 mentions)